Anti-Müllerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review  by Gasparin, Andrese Aline et al.
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(4):363–367
R
A
o
p
A
P
J
a
b
c
a
A
R
A
A
K
A
O
S
P
H
R
L
h
2www.reumato logia .com.br
REVISTA BRASILEIRA DE
REUMATOLOGIA
eview article
nti-Müllerian  hormone  levels  as a predictor  of
varian reserve  in systemic  lupus  erythematosus
atients: a review
ndrese Aline Gasparina,∗, Rafael Mendonc¸a da Silva Chakra, Claiton Viegas Brenolb,
enélope  Ester Palominosa, Ricardo Machado Xavierb, Lucian Souzac,
oão  Carlos Tavares Brenolb, Odirlei André Monticielob
Rheumatology Department, Hospital de Clínicas, Porto Alegre, RS, Brazil
Rheumatology Department, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 29 January 2014
ccepted 2 May 2014
vailable online 7 January 2015
eywords:
nti-Müllerian hormone
varian reserve
ystemic lupus erythematosus
a  b  s  t  r  a  c  t
The anti-Müllerian hormone (AMH) is secreted from granulosa cells of growing ovarian fol-
licles  and appears to be the best endocrine marker capable of estimating ovarian reserve.
Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects
women of reproductive age and may negatively affect their fertility due to disease activity
and  the treatments used. Recently, several studies assessed AMH  levels to understand the
real impact of SLE and its treatment on fertility.
© 2014 Elsevier Editora Ltda. All rights reserved.
Hormônio  anti-Mülleriano  como  preditor  de  reserva  ovariana  em
pacientes  lúpicas:  uma  revisão
alavras-chave:
ormônio anti-Mülleriano
eserva ovariana
úpus eritematoso sistêmico
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O hormônio anti-Mülleriano (HAM) é secretado a partir das células da granulosa dos folícu-
los  ovarianos em crescimento e parece ser o melhor marcador endócrino capaz de estimar a
reserva ovariana. O lúpus eritematoso sistêmico (LES) é uma doenc¸a autoimune que acomete
predominantemente mulheres em idade reprodutiva e pode afetar negativamente sua fer-tilidade pela atividade da
impacto do LES e de seu tr
os  quais têm usado o HAM
 Department of Rheumatology of Hospital de Clínicas of Porto Alegre
∗ Corresponding author.
E-mail: andresegasparin@gmail.com (A.A. Gasparin).
ttp://dx.doi.org/10.1016/j.rbre.2014.05.008
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved. doenc¸a, bem como pelos tratamentos usados. Conhecer o real
atamento na fertilidade vem sendo o objetivo de estudos recentes,
 para esse ﬁm.
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Fig. 1 – Anti-Müllerian hormone (AMH) and
folliculogenesis. AMH  is secreted by growing follicles and
secretion increases over follicular development. Highest
levels are secreted by preantral and small antral follicles.
AMH inhibits the initial recruitment of primary follicles
from the pool of primordial follicles and reduces the
sensitivity of antral follicles to follicle-stimulating hormone364  r e v b r a s r e u m a t
Introduction
Better treatment conditions and the management of infec-
tions have not only contributed to increase the survival of
systemic lupus erythematosus (SLE) patients, but also pro-
vided better quality of life, so nowadays most of these patients
are able to work normally. With the increasing participation of
women in the labor market, the moment they decide to have
their ﬁrst child has been increasingly postponed. Female fertil-
ity starts to decline at the beginning of the third decade of life
and could be hampered in SLE patients due to disease activ-
ity and its treatment. This makes fertility-related problems in
such patients more  and more  important, hence the need to
have effective markers to predict ovarian reserve.
Anti-Müllerian  hormone  as  an  ovarian  reserve
marker
Around the twentieth week of pregnancy, the number of
oocytes reaches a maximum of six to seven million and, in
a continuous process of atresia/apoptosis, only one to two
million follicles reach the neonatal period.1 Only oogonia that
enter meiosis will survive atresia in the fetal ovary before birth.
At menarche, around 300 thousand are viable. Women use
around 500 primordial follicles during the reproductive years.
At menopause, the ovary is formed by dense stroma and rare
remaining scattered oocytes.2
Follicular growth starts in the fetus, in a continuous pat-
tern, and is related to the total mass of follicles and with
factors released by atretic ovarian follicles. Follicular growth
cycles and subsequent atresia initiate before birth and con-
tinue through the reproductive years. The viability of the
oocyte declines in older women in reproductive age before
they present any measurable serum or intrafollicular hor-
mone concentration decrease.3 Menopause is associated with
a marked decline in the number of oocytes, which is attributed
to the progressive atresia of the original pool of oocytes. How-
ever, evidences of complete depletion of oocytes are currently
limited.3
The anti-Müllerian hormone (AMH), also called Müllerian-
inhibiting substance, is a polypeptide, member of the
transforming growth factor- (TGF) family. It is involved in
the sexual differentiation of the male embryo, inducing regres-
sion of the Müllerian duct, embryological precursor of the
female reproductive tract.4 In female individuals, it starts
expressing in the fetal ovary after the 36th week of pregnancy.
It is expressed by the granulosa cells of growing ovarian fol-
licles: primary, secondary, preantral and small antral, being
produced at higher levels by the last two.5 It has two main
mechanisms of action in the ovary: inhibits the initial recruit-
ment of primary follicles from primordial follicles, and inhibits
the sensitivity of antral follicles to follicle-stimulating hor-
mone (FSH) during cyclical recruitment (Fig. 1). The AMH
prevents the premature depletion of follicles.6 Despite the
“anti” preﬁx, the AMH  has no role in the production of anti-
bodies.
The term “ovarian reserve” describes the number and qual-
ity of the remaining oocytes in the ovaries. The amount of(FSH) during recruitment.
remaining primordial follicles appears to correlate with the
number of growing follicles. As only growing follicles produce
AMH, their plasma levels reﬂect the amount of remaining pri-
mordial follicles.7 Studies in mice8 and chimpanzees9 have
shown strong correlation between the levels of AMH  and the
number of primordial follicles.
Other current tests to estimate the ovarian reserve include
hormone (FSH, estradiol, inhibin B) and sonographic markers
(antral follicle count and measurement of ovarian volume).
These tests direct or indirectly reﬂect the number of remaining
antral follicles. Antral follicle count is a direct sonographic
measurement. In the early follicular phase, the levels of
inhibin B and estradiol are considered dependent on the num-
ber of antral follicles. FSH levels are regulated by negative
feedback of these two granulosa cell products, so they indi-
rectly reﬂect the pool of antral follicles. The age-related decline
of oocytes leads to reduced levels of estradiol and inhibin
B and, consequently, the increase of FSH.10 Compared with
these hormonal markers, AMH plasma levels appear to asso-
ciate better with the longitudinal decline of oocytes/follicles
over time, even before the occurrence of irregular cycles.11 As
opposed to the cyclic ﬂuctuations of FSH, estradiol and inhibin
B, the AMH has small or absent intracyclic ﬂuctuation. There-
fore, the AMH reﬂects the continued growth of small follicles.
AMH  levels are relatively unaffected by conditions that sup-
press late stages of FSH-dependent follicular development,
like pregnancy,12 the use of hormonal contraceptives13 and the
treatment with GnRH agonists. In addition to that, the AMH
does not appear to be affected by the body mass index (BMI) or
smoking.14 The predictive value of the AMH  to estimate ovar-
ian reserve is still uncertain. Several longitudinal prospective
studies following normo-ovulatory women for more  than 11
years have shown that the AMH is the best endocrine marker
to assess ovarian aging, and that AMH plasma levels, with
reasonable accuracy, can predict the onset of menopause.15
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Table 1 – Summary of published articles.
Study Design Follow-up Main results
Lawrenz et al.28 Case–control (33 patients in
each group)
February 2009 to May 2010,
Germany
SLE patients have signiﬁcantly lower AMH
levels than healthy controls.
Mok et al.29 Cohort study, 216 SLE
patients
June to October, 2009, China The mean AMH level was signiﬁcantly
lower in patients who had been
previously exposed to cyclophosphamide.
Morel et al.30 Case–control (56 patients in
each group)
2012, France Low AMH levels in SLE patients, with
signiﬁcant decrease associated with age
and prior use of cyclophosphamide.
Malheiro et al.31 Case–control (27 patients in Brazil The mean values of ovarian reserve were
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The AMH  appears to be an early, reliable and direct pre-
ictor of declining ovarian function. However, there is no
onsensus regarding appropriate threshold values. Literature
ata showed signiﬁcant dispersion of serum AMH concentra-
ions in comparable populations obtained from two different
ltrasensitive immunoassays available in the market – AMH
eckman Coulter ELISA and AMH Diagnostic System laboratories
DSL) ELISA.  A previous study found AMH  levels around 4.6
imes lower with the DSL kit, showing that the cut-off value
aries according to the assay being used.16 In studies that
ssessed the success rate of in vitro fertilization, serum AMH
evels below 0.5 ng/mL strongly suggested follicular depletion,
hile serum levels ≥1.26 ng/mL were consistent with a good
varian reserve.15,17
ow  can  lupus  systemic  erythematosus  impair  fertility?
nfertility is deﬁned as the failure to conceive after 12 months
f regular unprotected intercourse. Autoimmunity can inter-
ere with many  aspects associated with fertility, causing,
or example, tubal function changes, ovarian failure, embryo
mplantation failure and miscarriages.
A case–control study conducted in 2009 in Finland assessed
he reproductive history of SLE women compared with healthy
ontrols. The authors found no difference in the mean
ge at menarche and the frequency of infertility. However,
enopause occurred earlier among SLE patients.18
Around 10–30% of women with premature ovarian failure
POF) have a concomitant autoimmune disease.19 Autoim-
une reactions against ovaries can be general or partial,
eading to a ﬂuctuating course of POF. The evidence of
n autoimmune basis for POF is given by the presence of
ntibodies against steroid-producing cells in around 80% of
atients and oophoritis with inﬁltration of CD4+ and CD8+ T
ymphocytes.20
It is suggested that fertility in some patients could be
educed due to menstrual irregularities and anovulatory
ycles during disease activity and the administration of
igh doses of corticosteroids.21 At least 53% of SLE patients
nder the age of 40 present some degree of menstrual
rregularity, while menstrual alterations are more  frequent
mong patients with greater disease activity.22 The ovar-
an function can be reduced by autoimmune oophoritis in
LE, leading to POF, while a reduced ovarian reserve is
ssociated with reduced AMH  levels.23 Lupus nephritis can
esult in end stage renal disease and amenorrhea togethersimilar in both groups. SLE patients
showed wider distribution of AMH values.
with hyperprolactinemia.24 Around one third of SLE women
present antiphospholipid antibodies, which could explain the
SLE/miscarriage association.25
Therapeutic agents prescribed to treat SLE may impair fer-
tility, such as is the case of high doses of steroids, NSAIDs
and cyclophosphamide, which, in particular, inﬂuence the
ovarian function, especially at older ages. A study published
in 2006 found 39% of prevalence of ovarian failure among
patients treated with cyclophosphamide under the age of
30 and 59% of patients aged 30–40.26 A cohort study per-
formed from September 2010 to July 2011 in the United
States, comparing the reproductive history of young women
with rheumatic diseases, with or without prior exposure to
cyclophosphamide, concluded that more  women with prior
exposure to cyclophosphamide had amenorrhea, infertility
and nulliparity.27
Ovarian  reserve  assessment  in  premenopausal  SLE
patients  through  anti-Müllerian  hormone  –
state-of-the-art
Few studies using AMH to assess ovarian reserve in SLE
patients have been published to date. A case–control study
conducted in Germany from February 2009 to May 2010 ana-
lyzed the inﬂuence of SLE in ovarian reserve considering
disease activity and disease duration. The ovarian reserve was
determined through serum AMH levels in 33 premenopausal
SLE patients without prior exposure to cyclophosphamide and
in 33 age-matched control patients. AMH  levels in SLE patients
were signiﬁcantly lower than in healthy controls. No signiﬁ-
cant differences were found between the groups in relation to
the number of children and abortions, and there was no corre-
lation between the AMH level and the duration of the disease
or SLEDAI as a disease activity index. Despite presenting mild
disease activity, the ovarian reserve of SLE patients was signif-
icantly smaller than that of age-matched healthy controls.28
AMH levels and its relationship with age and prior expo-
sure to cyclophosphamide were investigated in a cohort of 216
Chinese SLE patients followed from July 2009 to October 2009.
It was found that the mean level of AMH  was signiﬁcantly
lower in patients who had prior exposure to cyclophos-
phamide, according to their ages. However, there was no
signiﬁcant differences when users or non-users of other
immunosuppressive agents, such as mycophenolate mofetil,
azathioprine and calcineurin inhibitors, were compared.29
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A case–control study conducted in 2012 in France found
low AMH  levels in SLE patients with signiﬁcant decrease
associated with age and prior use of cyclophosphamide. Nev-
ertheless, the risk of pregnancy failure was low (15.8%). The
prior use of cyclophosphamide was a predictor while AMH
levels were not.30
A case–control study with a small number of patients (27 in
each group) conducted in Brazil found similar mean ovarian
reserve values in both groups. However, SLE patients showed
broader distribution of AMH  levels. The ovarian function was
more  compromised in patients with higher cumulative dose
of cyclophosphamide and higher disease damage score.31 The
summary of the main articles published to date can be seen
in Table 1.
Conclusion
AMH  has been increasingly reported as a reliable marker of
ovarian reserve. The role of cyclophosphamide as the cause of
infertility, evidenced by lower levels of AMH in age-matched
and previously exposed patients, is well established. However,
further studies, with larger number of patients, are necessary
to assess differences in the ovarian reserve of SLE patients
when compared with controls, and the implications of dis-
ease activity on the fertility of these patients. Agents with less
ovarian toxicity could be offered to patients with reduced AMH
levels and to those who  wish to become pregnant.
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